Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin in Irritable Bowel Syndrome
NCT02009618Completed
- Sponsor
- Bezmialem Vakif University
- Start
- Jan 2013
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of rifaximin in irritable bowel syndrome (IBS), sponsored by Bezmialem Vakif University. Primary endpoint: Symptom Severity and Treatment Efficacy Scale at 6 weeks. Started Jan 2013; status: completed.
02
Drugs
rifaximin
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT02009618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02009618.